Application Note
*Optimal dilutions/concentrations should be determined by the researcher.
Application |
Recommended Dilution |
1:500~1:1000 |
Assay dependent |
Not tested in other applications.
Calculated MW
Product Note
Caspase 8 (cleaved Asp384) antibody detects endogenous levels of fragment of activated Caspase 8 resulting from cleavage adjacent to Asp384.
Form
Liquid
Buffer
PBS (without Mg²⁺ and Ca²⁺) pH7.4, 150mM NaCl, 50% Glycerol
Preservative
0.02% Sodium azide
Storage
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
Concentration
Batch dependent (Please refer to the vial label for the specific concentration.)
Antigen Species
Human
Immunogen
The antiserum was produced against synthesized peptide derived from human Caspase 8 (335-384).
Purification
Purified by antigen-affinity chromatography
From serum
Conjugation
Unconjugated
RRID
AB_10722501
Note
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Synonyms
ALPS2B , CAP4 , CASP8 , Casp8 , FLICE , MACH , MCH5 , caspase 8 , Caspase 8
Cellular Localization
Cytoplasm
Background
This gene encodes a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes composed of a prodomain, a large protease subunit, and a small protease subunit. Activation of caspases requires proteolytic processing at conserved internal aspartic residues to generate a heterodimeric enzyme consisting of the large and small subunits. This protein is involved in the programmed cell death induced by Fas and various apoptotic stimuli. The N-terminal FADD-like death effector domain of this protein suggests that it may interact with Fas-interacting protein FADD. This protein was detected in the insoluble fraction of the affected brain region from Huntington disease patients but not in those from normal controls, which implicated the role in neurodegenerative diseases. Many alternatively spliced transcript variants encoding different isoforms have been described, although not all variants have had their full-length sequences determined. [provided by RefSeq, Jul 2008]
Database
Research Area